The Division of Genomic Medicine services include genetic and genomic testing of cancer, as well as inherited conditions. The Division offers a diverse array of molecular genomic diagnostic services to assist with accurate diagnosis, risk-stratification, disease monitoring, as well as for matching the genetic profiles of individual tumors to appropriate targeted therapies. The goal of the Division is to provide clinicians and pathologists with comprehensive molecular and genomic diagnostic services beyond performing the tests, including consultation, appropriate molecular test selection as well as integrated results interpretation.
The Division includes the Cancer Cytogenetics, Cancer Genomics, and Molecular Oncology laboratories. Tests offered range from conventional cytogenetics and DNA microarray-based cytogenomic profiling, DNA and RNA-based next-generation sequencing (NGS) panels for mutations, copy number variation (CNV) and gene fusions, to targeted testing strategies, including fluorescence in situ hybridization (FISH), and single gene/target testing.
Genome-wide assay utilizing the Affymetrix OncoScan™ Array with Molecular Inversion Probe (MIP) technology for focal and large CNV and loss of heterozygosity (LOH).